A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon(R) in Patients With Nephropathic Cystinosis
Latest Information Update: 23 Dec 2024
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Nephropathic cystinosis
- Focus Pharmacokinetics; Registrational
- Sponsors Amgen; Raptor Pharmaceutical Inc
Most Recent Events
- 26 Jun 2014 New trial record